CLINICAL STUDIES ON CEFDINIR

We investigated the clinical efficacy and safety of cefdinir (CFDN) in 18 patients with respiratory tract infection (acute pharyngitis 1, acute tonsillitis 1, acute bronchitis 8, chronic bronchitis 1, pneumonia 5 and PAP 1), and 1 with acute pyelonephritis. Clinical response was excellent in 3 with...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 37; no. Supplement2; pp. 276 - 281
Main Authors TAKEBE, KAZUO, TAMURA, TOYOKAZU, ENDO, KATSUMI, KASAI, FUKIO, KUDO, KENJI, SAGARA, MORIO, OKAMOTO, KATSUHIRO, MASUDA, MITSUO, IMAMUR, KENICHI, KAWAGISHI, TAKAHIKO, MIYAZAWA, TADASHI
Format Journal Article
LanguageJapanese
Published Japanese Society of Chemotherapy 1989
Subjects
Cefdinir
Online AccessGet full text

Cover

More Information
Summary:We investigated the clinical efficacy and safety of cefdinir (CFDN) in 18 patients with respiratory tract infection (acute pharyngitis 1, acute tonsillitis 1, acute bronchitis 8, chronic bronchitis 1, pneumonia 5 and PAP 1), and 1 with acute pyelonephritis. Clinical response was excellent in 3 with acute pharyngitis, acute tonsillitis and acute pyelonephritis, excellent in 1 and good in 7 with acute bronchitis, excellent in 2, good in 2 and fair in 1 with pneumonia and poor in 1 with PAP. The overall efficacy rate was 94.1%(except one patient with PAP). No side effects related to the drug were observed. Laboratory findings revealed slight elevation of GOT and GPT in 2 cases. Consequently, we find CFDN to be a useful antibiotic in treating patients with bacterial respiratory and urinary tract infections.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.37.Supplement2_276